Sumary of Pfizer signs deal to let generic drug companies make its COVID-19 antiviral pill:
- Pfizer Inc. has signed a deal with a UN-backed group to allow other manufacturers to make its experimental COVID-19 antiviral pill, a move that could make the treatment available to more than half of the world’s population.
- In a statement issued Tuesday, Pfizer said it would grant a licence for the antiviral pill to the Geneva-based Medicines Patent Pool, which would let generic drug companies produce the pill for use in 95 countries, making up about 53 per cent of the world’s population.
- Still, health officials said the fact that the deal was struck even before Pfizer’s pill has been authorized anywhere could help to end the pandemic quicker.
- WATCH | Learn more about Pfizer’s experimental antiviral pill: Pfizer COVID-19 antiviral pill offers huge hope, says specialist11 days agoPfizer’s experimental antiviral pill for COVID-19 has great potential to drive down mass hospitalizations and reduce death, says infectious diseases specialist Dr. Zain Chagla.
- (Bebeto Matthews/The Associated Press) 4:49 “It’s quite significant that we will be able to provide access to a drug that appears to be effective and has just been developed, to more than four billion people,” Esteban Burrone, head of policy at the Medicines Patent Pool, said.
- Pfizer’s clinical trial halted after promising results Under the terms of the agreement, Pfizer will not receive royalties on sales in low-income countries, and will waive royalties on sales in all countries covered by the agreement while COVID-19 remains a public health emergency.
- Earlier this month, Pfizer said its clinical trial showed the pill cut the risk of hospitalization and death by between 85 and 89 per cent in people with mild to moderate coronavirus infections, if taken within three to five days of symptom onset.
- Pfizer said it would ask the U.S. Food and Drug Administration and other regulators to authorize the pill as soon as possible.